: Speaker List

Speaker View

Below is a listing of all sessions the speaker is scheduled to present.

Martin Warman

Vertex Pharmaceuticals, Inc.

Speaker Bio

Martin is a Scientific Fellow at Vertex Pharmaceuticals supporting the use of PAT within a QbD framework, from Development to use in Real Time Release. Prior to this he provided PAT consultancy services to the Pharmaceutical industry. He has over 17 years experience working in the field having previously lead the PAT Development Team of Pfizer Global Manufacturing.

Before joining Pfizer he worked for Dionex providing application support for liquid and supercritical fluid chromatography, including on-line measurements.

He joined Dionex from Shell Research, where he provided analytical support, developing novel environmental analysis methods and technologies in support of Shell's bio-restoration/bio-remediation projects, and environmental monitoring programs in the North Sea.

He has also worked in academia starting his career at the University of Westminster and unusually for an Analytical Chemist, his bachelor's degree is in Cell Biochemistry and is a qualified microbiologist.

This provides extensive, cross industry, experience in application identification, solution specification and delivery, as well as the support of systems during product life-cycle and he has experience in a developing and implementing a wide variety of measurement solutions, from spectroscopic, through chromatographic but including acoustic and particle characterisation.

Martin is also on the Executive Committee of ASTM E55 covering Pharmaceutical Manufacturing

Have a Question?

You can pose a question to the speaker by clicking on the "Suggest a Question" icon at the end of the session title. Appropriate questions will be answered during the session as time permits (not all questions will be answered).
Wednesday, March 30, 2011
Conference Program
Suggest A Question for this Session
PAT ' a Disjointed Product Approach or an Integrated Solution to Deliver Real Manufacturing Benefits?
Room: 1E12 ~ 2:00 pm - 3:30 pm (Wednesday, March 30, 2011)
The FDA's PAT initiative was in response to a desire for innovation in manufacturing and quality assurance. Nearly a decade later, industry remains reticent to embrace the principles espouse by the PAT guidance. Tools mentioned in the guidance seem to have been utilized but the goals of the PAT guidance, or for that matter the improvement in manufacturing and quality assurance have not been realized.
Is this because of "product focused" marketing of PAT tools? Can the PAT framework be embraced and implemented until the venders begin to offer "solution packages" which include PAT tools and principles? Join us for a round table discussion.
Ali Afnan, Step Change Pharma, Inc.
Kevin Bittorf, Vertex Pharmaceuticals Inc.
Martin Gadsby - Director, Optimal Industrial Automation Limited
Reed Exhibitions
  • Pharmaceuticals
  • Biologics
  • Generics
  • Contract Services
ConferencePath System © 2004 - 2015 ConferencePath & MasseyMedia. All Rights Reserved.